ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam Sells 16,809 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam sold 16,809 shares of the business’s stock in a transaction on Friday, April 19th. The stock was sold at an average price of $65.17, for a total transaction of $1,095,442.53. Following the transaction, the chief operating officer now owns 782,620 shares of the company’s stock, valued at approximately $51,003,345.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Muthusamy Shanmugam also recently made the following trade(s):

• On Wednesday, April 17th, Muthusamy Shanmugam sold 9,520 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.40, for a total value of $622,608.00.
• On Monday, April 15th, Muthusamy Shanmugam sold 7,414 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.33, for a total value of $491,770.62.
• On Thursday, March 7th, Muthusamy Shanmugam sold 15,085 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $66.35, for a total transaction of $1,000,889.75.
• On Tuesday, March 5th, Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $65.35, for a total transaction of $659,577.55.

ANI Pharmaceuticals Stock Up 0.8 %

Shares of NASDAQ ANIP opened at $66.14 on Wednesday. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of 78.74 and a beta of 0.79. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. The firm has a 50-day moving average price of $65.12 and a 200 day moving average price of $58.70. ANI Pharmaceuticals, Inc. has a 52 week low of $36.99 and a 52 week high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The company had revenue of $131.65 million for the quarter, compared to analyst estimates of $123.02 million. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. Equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current fiscal year.

Analysts Set New Price Targets

ANIP has been the subject of several research reports. Truist Financial upped their price target on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Guggenheim reaffirmed a “buy” rating and set a $77.00 price objective on shares of ANI Pharmaceuticals in a research report on Tuesday. Capital One Financial began coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an “overweight” rating and a $80.00 target price for the company. Finally, HC Wainwright increased their price target on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a report on Monday, March 4th. Five analysts have rated the stock with a buy rating, According to MarketBeat, ANI Pharmaceuticals currently has an average rating of “Buy” and an average target price of $80.00.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of large investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC raised its stake in ANI Pharmaceuticals by 287.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,277 shares of the specialty pharmaceutical company’s stock valued at $1,471,000 after purchasing an additional 15,790 shares during the last quarter. BTC Capital Management Inc. acquired a new position in shares of ANI Pharmaceuticals in the first quarter valued at approximately $580,000. Los Angeles Capital Management LLC lifted its stake in shares of ANI Pharmaceuticals by 27.6% during the first quarter. Los Angeles Capital Management LLC now owns 24,974 shares of the specialty pharmaceutical company’s stock valued at $1,726,000 after buying an additional 5,408 shares during the period. Clear Street Markets LLC acquired a new stake in ANI Pharmaceuticals during the fourth quarter worth approximately $140,000. Finally, Comerica Bank boosted its position in ANI Pharmaceuticals by 4.6% during the fourth quarter. Comerica Bank now owns 36,855 shares of the specialty pharmaceutical company’s stock worth $2,032,000 after acquiring an additional 1,626 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.